Version 1
: Received: 5 December 2023 / Approved: 6 December 2023 / Online: 7 December 2023 (07:37:29 CET)
How to cite:
Leporace-Jimenez, F.; Portillo-Hernandez, I.; Jimenez-Almonacid, J.; Rodriguez, I.Z.; Mejía-Nieto, M.; Caballero Pedrero, P.; Sanchez-Aniceto, G. Revisiting the Role of PD-L1 Overexpression in Prognosis and Clinicopathological Features in Patients with Oral Squamous Cell Carcinoma. Preprints2023, 2023120439. https://doi.org/10.20944/preprints202312.0439.v1
Leporace-Jimenez, F.; Portillo-Hernandez, I.; Jimenez-Almonacid, J.; Rodriguez, I.Z.; Mejía-Nieto, M.; Caballero Pedrero, P.; Sanchez-Aniceto, G. Revisiting the Role of PD-L1 Overexpression in Prognosis and Clinicopathological Features in Patients with Oral Squamous Cell Carcinoma. Preprints 2023, 2023120439. https://doi.org/10.20944/preprints202312.0439.v1
Leporace-Jimenez, F.; Portillo-Hernandez, I.; Jimenez-Almonacid, J.; Rodriguez, I.Z.; Mejía-Nieto, M.; Caballero Pedrero, P.; Sanchez-Aniceto, G. Revisiting the Role of PD-L1 Overexpression in Prognosis and Clinicopathological Features in Patients with Oral Squamous Cell Carcinoma. Preprints2023, 2023120439. https://doi.org/10.20944/preprints202312.0439.v1
APA Style
Leporace-Jimenez, F., Portillo-Hernandez, I., Jimenez-Almonacid, J., Rodriguez, I.Z., Mejía-Nieto, M., Caballero Pedrero, P., & Sanchez-Aniceto, G. (2023). Revisiting the Role of PD-L1 Overexpression in Prognosis and Clinicopathological Features in Patients with Oral Squamous Cell Carcinoma. Preprints. https://doi.org/10.20944/preprints202312.0439.v1
Chicago/Turabian Style
Leporace-Jimenez, F., Pablo Caballero Pedrero and Gregorio Sanchez-Aniceto. 2023 "Revisiting the Role of PD-L1 Overexpression in Prognosis and Clinicopathological Features in Patients with Oral Squamous Cell Carcinoma" Preprints. https://doi.org/10.20944/preprints202312.0439.v1
Abstract
Background: PD1 and its ligand PD-L1 are related to the prognosis in many solid tumors, whether its role in oral squamous cell carcinoma (OSCC) remains unclear. Methods: Retrospective monocentric study including all patients with OSCC diagnosed and treated between 01/2020 and 05/2022. PD-L1 expression was assessed by combined positive score (CPS), considering CPS > or equal to 1 as positive (1-20 “low expression”, and ≥20 “high”). Descriptive analysis of patient cohort and tumors was performed, including tumor size, stage, lymph node involvement, recur-rence and survival. Results: 65 patients (65 tumors) were analyzed. 66.15% of tumors were ad-vanced stages (III-IV), of them, 97.67% PD-L1+ versus 71.42% within early stages (I-II). T4 tumors expressed PD-L1 in 100% of cases, compared with 54’54% in T1 tumors. 50.79 % of tumors showed lymph node involvement (pN+), 100% of them showing PD-L1+. Prevalence of pN+ was 59.38% for PD-L1 high expression versus 40.63% for low expression. Patients' follow-up ranged from 2 to 34.5 months. No significant difference was seen between overall survival (OS) and PD-L1 +/- (CPS ≥1 vs CPS <1) neither PD-L1 high (CPS ≥20) vs low CPS <20) (p 0.97 and 0.64, re-spectively). Conclusions: The method used to measure (laboratory test with Dako 22C3 an-ti-PD-L1 primary antibody) PD-L1 was reliable and accurate, with a correlation coefficient be-tween the PD-L1 expression in the biopsy and surgical piece of 0.83 (p 0.0001). CPS≥1 was ob-served in large tumors (p<0.001), and was correlated with of lymph node metastases (p<0.004). Further analysis of PD-L1 expression and its relevance in tumor biology and prognosis is needed.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
